omniture
logo
Search

Statement by WuXi AppTec Regarding Recent Market Fluctuation

WuXi AppTec
2021-12-16 08:00 2487

SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the world. We will provide any new information as warranted and in compliance with applicable laws and regulations.

 

Cision View original content:https://www.prnewswire.com/news-releases/statement-by-wuxi-apptec-regarding-recent-market-fluctuation-301445967.html

Source: WuXi AppTec
Media Room more

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

2024-11-12 08:00
1101

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

2024-10-30 08:00
1180

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

2024-10-28 19:03
1874

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

2024-07-29 19:05
4312

WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations

2024-04-29 19:00
2067

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time

2024-03-18 20:32
2595
Related News

International Genomics Conference (ICG-19) Opens at BGI Group HQ in Shenzhen

2024-11-22 21:57
2220
Professor Huanming Yang, Co-Founder of BGI Group, delivered a keynote address on milestones in genomics (PRNewsfoto/BGI Group)

FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer

2024-11-22 16:00
1896

Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity

2024-11-22 12:14
1395

Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology

2024-11-22 10:27
1437

The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

2024-11-21 23:46
931

I-Mab to Participate at the Piper Sandler Healthcare Conference

2024-11-21 20:00
962
collection